Horizon Therapeutics plc: New Integrated Data and Follow-up Outcomes From Two TEPEZZA (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
(0) -- TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline -- -- For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 percent had a proptosis response, 69 percent had a diplopia response and 83 percent had an ophthalmic composite outcome response -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in The Lancet Diabete...
Source: finanznachrichten.de